MAIA Biotechnology financials
$1.15−2.54%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$24.3M | -$17.0M | -$20.2M | -$15.9M |
| Net income | -$22.4M | -$23.3M | -$19.8M | -$16.2M |
| Net margin | — | — | — | — |
| Diluted EPS | $-0.70 | $-1.05 | $-1.49 | $-1.75 |
| EBITDA | -$24.3M | -$17.0M | -$20.2M | -$15.9M |
| Operating cash flow | -$18.8M | -$15.7M | -$13.1M | -$12.1M |
| Free cash flow | -$18.8M | -$15.7M | -$13.1M | -$12.1M |
| Diluted shares | 32.1M | 22.2M | 13.3M | 9.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $8.7M | $9.6M | $7.2M | $11.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $9.7M | $10.2M | $7.6M | $12.0M |
| Total liabilities | $7.3M | $6.5M | $7.1M | $3.5M |
| Shareholders' equity | $2.4M | $3.6M | $477.5K | $8.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology